Cardior Pharmaceuticals GmbH has appointed Axel-Sven Malkomes as chief financial officer as it advances its pipeline of non-coding RNA-based therapeutics for patients with cardiac diseases. Mr Malkomes joins from Medigene AG, the cell and gene therapy company, where he was responsible for finance and business development. Before that, he held healthcare investment banking positions at Barclays Investment Bank and Société Générale. He has also led European healthcare investments at 3i Group Plc, a private equity firm. Mr Malkomes holds a business administration degree from the Otto-Friedrich University in Germany.
Cardior announced the appointment on 3 November 2022.
Copyright 2022 Evernow Publishing Ltd